Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT02076178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2014
Completion date
February 23, 2016
Enrollment
127 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus